IMPROVE-IT
2015
Improved Reduction of Outcomes: Vytorin Efficacy International Trial
In 18,144 patients post-ACS, ezetimibe added to simvastatin further reduced CV death, MI, UA, revasc or stroke compared with simvastatin alone.
Result
Efficacy: Composite CV eventsHR 0.94
Below 1 favours ezetimibe added to simvastatin, above 1 favours simvastatin alone.
- Absolute difference
- 2.0 points
The absolute difference is derived from the event rates.
Also reported: Mean LDL 54 vs 70 mg/dL.
- Subtopic
- Non-statin LDL
- Design
- Double-blind RCT, median 6 yr
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 CCSESC 2023 ACSESC/EAS LipidsESC 2021 PreventionACC/AHA 2025 ACSACC/AHA 2023 CCDACC/AHA 2026 Dyslipidaemia
- Source
- Cannon CP, et al. N Engl J Med. 2015;372(25):2387-2397.doi 10.1056/NEJMoa1410489
Discussion & critique
First non-statin LDL trial to show outcome benefit: validated the 'lower-is-better' LDL hypothesis. Modest absolute risk reduction; cost-effectiveness debated.